RIOK2 and prostate carcinoma: RIOK2 was previously confirmed to be highly expressed and over-activated in non-small cell lung cancer, prostate cancer, and glioblastoma, driving the occurrence and development of related tumors (Read et al., 2013; Liu et al., 2016; Liu et al., 2018; Mohamed et al., 2018; Delman et al., 2019; Song et al., 2020).